AVE-1625 is a highly potent, selective antagonist for the CB1 receptor (Ki = 0.16-0.44 nM). At low concentrations, AVE-1625 significantly improves the performance of rodents in working memory tasks. At higher concentrations, AVE-1625 reduces caloric intake, increases lipolysis from fat tissues, and reduces hepatic glycogen levels in rodents.
